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Objective: The presence of minority nonnucleoside reverse transcriptase inhibitor
(NNRTI)-resistant HIV-1 variants prior to antiretroviral therapy (ART) has been linked
to virologic failure in treatment-naive patients.
Design: We performed a large retrospective study to determine the number of treat-
ment failures that could have been prevented by implementing minority drug-resistant
HIV-1 variant analyses in ART-naı¨ve patients in whom no NNRTI resistance mutations
were detected by routine resistance testing.
Methods: Of 1608 patients in the Swiss HIV Cohort Study, who have initiated first-line
ARTwith two nucleoside reverse transcriptase inhibitors (NRTIs) and one NNRTI before
July 2008, 519 patients were eligible by means of HIV-1 subtype, viral load and sample
availability. Key NNRTI drug resistance mutations K103N and Y181C were measured
by allele-specific PCR in 208 of 519 randomly chosen patients.
Results: Minority K103N and Y181C drug resistancemutations were detected in five out
of 190 (2.6%) and 10 out of 201 (5%) patients, respectively. Focusing on 183 patients for
whom virologic success or failure could be examined, virologic failure occurred in seven
out of 183 (3.8%) patients; minority K103N and/or Y181C variants were present prior to
ART initiation in only two of those patients. The NNRTI-containing, first-line ART was
effective in 10 patients with preexisting minority NNRTI-resistant HIV-1 variant.
Conclusion: As revealed in settings of case–control studies, minority NNRTI-resistant
HIV-1 variants can have an impact on ART. However, the implementation of minority
NNRTI-resistant HIV-1 variant analysis in addition to genotypic resistance testing (GRT)
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Introduction
HIV type 1 (HIV-1) establishes a chronic infection that is
incurable to date. Combination antiretroviral therapy
(ART) substantially decreases the morbidity and mortality
in HIV-1 infected patients [1]. To achieve this outcome,
the majority of patients have to be treated lifelong. This
goes along with the risk of virologic failure and
development of drug resistance that limits further
treatment options [2,3]. Furthermore, as drug-resistant
viruses can be transmitted, it is recommended to test for
the presence of drug resistance mutations before initiating
ART in treatment-naive patients [4].
Routine genotypic resistance testing based on population
sequencing (GRT) misses minority drug-resistant HIV-1
variants representing less than 20–25% of the virus
population [5–7]. The application of more sensitive
technologies to detect and quantify minority drug-resistant
HIV-1 variants has revealed that these low abundant
viruses can cause virologic failure especially in the context
of ART regimens with a low genetic barrier to resistance,
for instance, nonnucleoside reverse transcriptase inhibitor
(NNRTI)-containing regimens [8–11]. A pooled analysis
of 10 studies and almost 1000 patients has shown that
preexisting minority NNRTI-resistant HIV-1 variants are
associated with virologic failure [9]. A recent European
multicohort case–control study [11] of 368 individuals
using centralized ultrasensitive 454 sequencing showed a
significantly increased risk of virologic failure to first-line
NNRTI-based ARTwhen minority drug-resistant HIV-1
variants preexisted. These studies were designed as
case–control or cohort studies focusing on patients
experiencing virologic failure [9].
Current antiretroviral regimens are very efficient and
the number of virologic failures due to drug resistance
is low in ART-naive patients. However, to minimize
this risk of virologic failure of first-line ART even
further, it is currently discussed to implement more
sensitive genotypic resistance testing in routine clinical
settings to detect systematically preexisting minority
drug-resistant HIV-1 variants. To answer this, we have
designed a study composed of a representative group
of patients from the nation-wide, observational Swiss
HIV Cohort Study (SHCS). Patients selected for
inclusion were ART-naive, started with a NNRTI-
containing ART and in whom no NNRTI or NRTI
resistance mutation was detected by routine GRT prior
to ART. Minority drug-resistant HIV-1 variants were
measured and analysed in the context of virologic success
or failure.
Materials and methods
Study participants and study design
The SHCS is an observational, nation-wide cohort,
including at least 45% of the cumulative number of HIV-1
infected individuals declared to the Swiss health
authorities [12]. The inclusion criteria for this substudy
were as follows: chronic infection with HIV-1 subtype
B or 01_AE, start of first-line ART with NNRTI and
two NRTIs before 1 July 2008, no NNRTI or NRTI
resistance mutations prior to ART detected by popula-
tion sequencing, baseline viral load above 1000 HIV-1
RNA copies/ml plasma and available plasma sample
within 6 months before initiation of first-line ART.
Random selection was performed within strata of HIV-1
subtype and time periods (4-year intervals of estimated
year of HIV-1 infection between 1980 and 2008; time
band sampling). The number of samples per stratum was
selected proportionally to the fraction observed in all
eligible patients. The infection date was estimated
according to the method developed by P. Taffe´ and M.
May [13]. The SHCS has been approved by ethical
committees from all participating institutions and written
informed consent has been obtained from all individuals
[12].
Twenty-four months follow-up data were used to
differentiate two groups of patients: those who experi-
enced virologic failure and those who were success-
fully treated. Virologic failure was defined as virologic
rebound with two consecutive viral loads more than
200 HIV-1 RNA copies/ml plasma after having
achieved a viral load less than 50 copies/ml after initiation
of first-line ARTor one viral load of more than 200 HIV-
1 RNA copies/ml plasma after 6–24 months of con-
tinuous treatment, followed by a modification of
treatment or as virologic nonresponse, that is failing
to achieve a decrease in viral load less than 200 HIV-1
RNA copies/ml plasma within 16 weeks of continuous
treatment.
Viral load, resistance testing and allele-specific
real-time PCR
Plasma HIV-1 viral load was quantified and genotypic
resistance testing by population sequencing was
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performed as described [14]. Drug resistance mutations
were defined as recommended by the International
Antiviral Society-USA (IAS-USA) Drug Resistance
Mutations Group and the surveillance drug resistance
mutations list [2,15]. Minority K103N, Y181C and
M184V drug-resistant HIV-1 variants were quantified
by allele-specific real-time PCRs (AS-PCRs) as pre-
viously described in detail [10,14,16–18]. Each AS-PCR
has a dynamic range of six logs and a detection limit
of 10 HIV-1 DNA copies per reaction. The discrimi-
natory abilities are as follows: 0.01% for the K103N,
0.2% for the Y181C and M184V mutations. Mutational
load was calculated by multiplying the percentage of
a given minority drug-resistant HIV-1 variant with the
viral load.
Data and statistical analyses
Clinical data from the SHCS were used as well as HIV-1
pol sequences from the SHCS drug resistance database,
which are stored in SmartGene’s Integrated Database
Network System (IDNS version 3.6.6) [19]. Statistical
analyses were performed with Stata 12 SE software
(Stata Corp., College Station, Texas, USA). All P values
were two-sided, and the level of significance was set
at 0.05.
Results
Baseline characteristics
The SHCS comprised 15 857 participants on 30 June
2010. One thousand, six hundred and eight participants
were chronically HIV-1 infected, ART-naive and started
first-line ART containing one NNRTI and two NRTIs
before 1 July 2008 (Fig. 1). Another inclusion criterion
was the infection with HIV-1 subtype B or 01_AE, which
was necessary, because the AS-PCR primer design is only
optimal for those two subtypes. For other HIV-1
subtypes, individual confirmation of the homology of
primer binding sites would have been necessary that could
potentially have jeopardized the random selection of
patients. As shown in Fig. 1, 519 patients were deemed
eligible for this study, of whom 221 individuals were
randomly selected for minority drug-resistant HIV-1
variant testing. Finally, data from 208 patients were
included in the analysis. Thirteen exclusions were due to
sample unavailability, previously not reported NNRTI or
NRTI resistance in the majority of viruses, or
unsuccessful RT-PCR (Fig. 1).
These 208 patients were representative of all 519 eligible
patients, thus representing chronically HIV-1 subtype
B or 01_AE infected patients in Switzerland receiving
Minority variant testing in routine clinical settings Metzner et al. 2233
15 857 patients (Swiss HIV Cohort Study, 06/30/2010) 
519 patients 
Randomized selection 
221 patients 
Received samples 
213 patients 
Excluded patients: 
• K103N as majority HIV-1 variant (1 patient)
• No successful RT-PCR (4 patients)  
208 patients 
AS-PCR result did not pass quality criteria: 
• K103N (18 samples)
• Y181C (7 samples)
• M184V (3 samples)   
1608 patients  
Inclusion criteria: 
• Baseline viral load >1000 HIV-1 RNA copies/ml plasma
• No baseline NNRTI- or NRTI resistance mutations (GRT)
• HIV-1 subtype B or 01_AE
• Available plasma sample within 6 months before initiation of ART     
• Chronic HIV-1 infection (≥6 months after primary HIV-1 infection)
• ART-naive
• First-line ART: NNRTI + 2 NRTIs
• Start of ART before July 1st 2008    
K103N: 190 patients (167 with 24 months follow-up)
Y181C: 201 patients (176 with 24 months follow-up)
M184V: 205 patients (180 with 24 months follow-up) 
 
 
Fig. 1. Scheme of study design.
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first-line, NNRTI-containing ART. No significant
differences were observed in terms of age, sex, ethnicity,
route of transmission, estimated year of HIV-1 infection,
CD4þ cell count and viral load at baseline, and first-line
ART regimens (Table 1). It has to be noted that certain
clinical parameters differed significantly between the 519
eligible patients and the remaining 1089 of all 1608
patients who started first-line treatment with an NNRTI-
containing regimen. Due to the exclusion of almost all
HIV-1 non-B subtypes, these groups differed in terms of
sex distribution, transmission routes, ethnicity and,
naturally, HIV-1 subtype distribution (data not shown).
Patients who matched our inclusion criteria were
predominantly white MSM and were infected with
HIV-1 subtype B. Both groups did not differ in terms of
the rate of virologic failure, viral load prior to initiation of
ART and first-line NNRTI.
Low prevalence of preexisting minority
nonnucleoside reverse transcriptase inhibitor-
resistant HIV-1 variants in antiretroviral therapy-
naive patients in routine clinical settings and
missing association with virologic failure
Minority NNRTI-resistant HIV-1 variants were present
prior to first-line NNRTI-containing ART in 14 of
208 patients (6.7%). The K103N mutation was detected
in five out of 190 (2.6%) patients at frequencies of
0.08–7.46% (3 x <1%, 2 x >2%) and the Y181C
mutation in 10 out of 201 (5%) patients at frequencies of
0.5–2.7% (7 x<1%, 2 x 1–2%, 1 x>2%). Calculating the
mutational load, that is the total amount of HIV-1 RNA
copies/ml plasma carrying a drug resistance mutation, the
results were as follows: K103N: 104–20 579 (3 x <1000,
2 x >2000) and Y181C: 215–6489 (9 x <1000, 1 x
>2000) mutant HIV-1 RNA copies/ml plasma. The
M184V mutation was verified in one of 205 (0.5%)
patients representing 0.9% of the virus population, that
is 91 mutant HIV-1 RNA copies/ml plasma. Virus
replication was successfully suppressed in this patient.
Figure 2 depicts 12/14 patients who were followed-up
for 24 months.
For 183 of the 208 randomly chosen patients, virologic
success or failure could be examined, because 24 or more
months of follow-up was available. Twenty-five patients
were not eligible for this analysis due to the following
reasons: two patients died, two were lost to follow-up,
13 patients switched to another regimen due to side
effects, four patients decided to switch or stop treatment,
and in four patients the reason for discontinuation of
treatment was unknown; virological failure was not
reported, and two patients harboured the Y181C muta-
tion as minority variant.
Of those 183 patients, 176 patients (96.2%) were
virologically suppressed until month 24 while receiving
their first-line, NNRTI-containing regimen. Seven
patients (3.8%) experienced virologic failure as defined
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Table 1. Baseline characteristics of randomized/tested patients and remaining patients of a total of 519 eligible patients in the investigation of
usefulness of implementing more sensitive drug resistance assays in routine clinical settings.
Clinical parameter
Randomized/tested
patients (n¼208)
Not tested
patients (n¼311) P
Age, median (IQR), years 39 (32–45) 39 (34–45) 0.159
Sex, No. (%) Male 170 (81.7) 263 (84.6) 0.395
Female 38 (18.3) 48 (15.4)
Ethnicity, no. (%) White 188 (90.4) 279 (89.7) 0.802
Nonwhite 20 (9.6) 32 (10.3)
Route of transmission, no. (%) MSM 114 (54.8) 178 (57.2) 0.841
Het 67 (32.2) 93 (29.9)
IDU 27 (13.0) 40 (12.9)
HIV-1 subtype, no. (%) B 198 (95.2) 292 (93.9) 0.527
01_AE 10 (4.8) 19 (6.1)
Estimated year of HIV-1 infection, median (IQR),
years
1999 (1995–2001) 1998 (1995–2001) 0.582
CD4þ cell count median (IQR), cells/ml blood 218.5 (159.5–292) 216 (150–308) 1
HIV-1 viral load, median (IQR), log10 HIV-1
RNA copies/ml plasma
4.9 (4.5–5.3) 4.9 (4.4–5.2) 0.276
start of first-line ART, median (IQR), years 2005 (2003–2007) 2005 (2002–2006) 0.086
NNRTI, no. (%) EFV 180 (86.5) 275 (88.4) 0.522
NVP 28 (13.5) 36 (11.6)
NRTI, no. (%) ZDV and 3TC 73 (35.1) 135 (43.4) 0.295
TDF and FTC 61 (29.3) 86 (27.6)
TDF and 3TC 31 (14.9) 44 (14.2)
ABC and 3TC 21 (10.1) 21 (6.8)
Others 22 (10.6) 25 (8.0)
Virologic outcome of first-line ART, no. (%) n¼183 n¼288
Virologic success 176 (96.2) 269 (93.4) 0.199
Virologic failure 7 (3.8) 19 (6.6)
ABC, abacavir; 3TC, lamivudine; EFV, efavirenz; FTC, emtricitabine; Het, heterosexual; HIV-1, human immunodeficiency virus type 1; IDU,
intravenous drug use; IQR, interquartile range; MSM, men who have sex with men; NNRTI, nonnucleos/tide reverse transcriptase inhibitor; NRTI,
nucleos/tide reverse transcriptase inhibitor; NVP, nevirapine; TDF, tenofovir; ZDV, zidovudine.
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in the Materials and Methods section (Table 1). Two of
them harboured minority NNRTI-resistant HIV-1
variants prior to first-line ART (Fig. 2). In patient 8,
who failed with the exclusive selection of the M184I
mutation, 0.6% of the virus population carried the
Y181C mutation prior to ART. Patient 13, who
harboured both NNRTI mutations in high mutational
loads prior to ART, failed rapidly within the first
4 months, accompanied by the selection of K103N and
Y181C mutations (Fig. 2). For this patient, a likely
association existed between preexisting minority
NNRTI-resistant HIV-1 variants and virologic failure.
However, the virologic failures in the other five patients
cannot be explained by the preexistence of minority
Minority variant testing in routine clinical settings Metzner et al. 2235
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Fig. 2. Preexisting minority nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 variants and virologic outcome of
first-line, nonnucleoside reverse transcriptase inhibitor containing antiretroviral therapy. Plasma viral load was measured using
Cobas AmpliPrep/Cobas TaqMan HIV-1 Test, versions 1 and 2.0 (black circles). The limit of detection was fixed to 50 HIV-1 RNA
copies/ml plasma and is shown in dashed lines. Minority K103N (open triangles) and Y181C (open diamonds) HIV-1 variants were
quantified by AS-PCR; percentages are given and were used to calculate the absolute amounts of these variants based on the viral
load. Periods of ART are depicted in grey shaded areas. /r, ritonavir-boosted; 3TC, lamivudine; ART, antiretroviral therapy; ATV,
atazanavir; EFV, efavirenz; FTC, emtricitabine; GRT, genotypic resistance testing; LPV, lopinavir; NVP, nevirapine; TDF, tenofovir;
ZDV, zidovudine.
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K103N or Y181C HIV-1 variants. In contrast, another
10 patients harboured minority NNRTI-resistant HIV-1
variants prior to first-line ART without experiencing
virologic failure (Fig. 2).
As the number of well defined virologic failures was low
(seven patients of whom just two harboured preexisting
minority NNRTI-resistant HIV-1 variants), we measured
minority NNRTI-resistant HIV-1 variants in additional
10 patients from the 19 not tested patients experiencing
virologic failure (Table 1). The K103N mutation was not
detected in any of those patients. The Y181C mutation
was detected in one of 10 patients prior to ART at a
frequency of 0.5%, that is 725 Y181C RNA copies/ml
plasma. This patient showed the following drug resistance
mutations during virologic failure: K65R, K103N,
Y181C and M184V. In total, three of 13 patients carrying
minority NNRTI-resistant HIV-1 variants prior to first-
line ARTexperienced virological failure. This results in a
positive predictive value for any of these minority
NNRTI resistance mutations of 23% meaning that first-
line, NNRTI-containing ART would be wrongfully
withheld from a large proportion of patients. Vice versa,
in a total of 17 patients experiencing virological failure,
only three harboured minority NNRTI-resistant variants
prior to ART.
Discussion
We performed an investigation to test the hypothesis
that additional implementation of more sensitive assays
for the detection of minority drug-resistant HIV-1
variants in routine clinical settings would prevent those
few virologic failures in treatment-naive patients who are
initiating ART with a NNRTI-containing regimen,
although the routine genotypic resistance test based on
population sequencing does not detect any NNRTI
resistance mutation. The SHCS reported low virologic
failure rates in patients receiving an NNRTI-containing,
first-line regimen: 45 out of 805 (6%) patients starting
ART between 1999 and 2005 [19]. Our most recent
analysis, including all patients between 1999 and June
2008, showed no change in the rate of virologic failure
(84/1309; 6.4%). And our inclusion criteria, such as
HIV-1 subtype B or 01_AE, did not change this either
(26/471; 5.5%). Minority NNRTI-resistant HIV-1
variants were measured by AS-PCR in 208 randomly
chosen patients to determine whether more sensitive
genotypic resistance testing would have prevented those
virologic failures. Similar to the low rate of virologic
failure, the prevalence of preexisting minority NNRTI-
resistant HIV-1 variants was low. Yet, the observed
overlap was minimal, meaning that only two out of seven
patients with virologic failure harboured preexisting
minority NNRTI-resistant HIV-1 variants, whereas only
two out of 12 patients with preexisting minority
NNRTI-resistant HIV-1 variants experienced virologic
failure. Minority M184V variants were irrelevant in
our cohort.
These results are contradictory to a pooled analysis of
10 studies [9] and a recent European multicohort case–
control study, both showing an increased risk of virologic
failure to first-line NNRTI-based ART when minority
drug-resistant HIV-1 variants were detected prior to
ART [11]. However, when separately examining each of
these studies included in the pooled analysis [9], it shows
that all four case–control studies resulted in a significant
association between virologic failure and preexisting
minority drug-resistant HIV-1 variants in ART-naive
individuals [10,20–22], but four of the included six
cohort studies did not reveal this association [23–26]. In
terms of the other two cohort studies, an association was
found when the mutational load was more than 2000
K103N copies/ml plasma [27] or when all preexisting
NNRTI-resistance mutations were included in the
analysis independent of their frequency [28]. In the
meantime, three other cohort studies have been published
and none of them show an association between virologic
failure and preexisting minority drug-resistant HIV-1
variants in ART-naive individuals [29–31]. This failure in
detecting an association could be due to the small number
of individuals included in most of the cohort studies
(n< 100 in each study), but in the most recently
published study, more than 200 individuals were included
[29].
By measuring only the K103N, Y181C and M184V
mutations, we might have missed other important and
maybe more predictive drug resistance mutations.
However, almost all analyses on the impact of preexisting
minority drug-resistant HIV-1 variants on NNRTI-
containing regimens are based on AS-PCR focusing
exactly on these three mutations, which are key drug
resistance mutations [9]. It might be possible to close this
gap by applying next-generation technologies, but this
technology has currently a lower sensitivity than AS-
PCR [32,33]. Noteworthy, expanding the spectrum of
measured drug resistance mutations would not change the
observation that most of the patients harbouring
preexisting minority NNRTI-resistant HIV-1 variants
were successfully treated with an NNRTI-containing
regimen. Thus, for those patients, NNRTIs would have
been wrongly withheld.
The mutational load, that is the absolute number of
viruses harbouring drug resistance mutations within the
viral population, might be more predictive for virologic
failure than the percentage of minority drug-resistant
variants. It has been shown that a preexisting mutational
load of more than 2000 K103N HIV-1 RNA copies/ml
plasma, quantified by AS-PCR specific for this mutation,
is highly predictive of virologic failure in patients starting
with a first-line, NNRTI-containing regimen [27].
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Patient 13 harboured more than 20 000 K103N and more
than 6000 Y181C HIV-1 RNA copies/ml plasma prior
to ART, whereas the mutational load was less than
2000 copies/ml in all other patients. Also, in a recent
pooled analysis of almost 1000 patients, an increase of the
mutational load was associated with an increased risk of
virologic failure, but the risk increased already signifi-
cantly at low mutational loads of 10–99 copies/ml plasma
[9].
We studied the impact of preexisting minority NNRTI-
resistant HIV-1 variants on the outcome of NNRTI-
containing, first-line ART in a retrospective manner.
Undoubtedly, a prospective study would be the ultimate
concept to proof or to deny the relevance of those
minority NNRTI-resistant HIV-1 variants on the out-
come of first-line regimens, particularly for treatments
with a low genetic barrier to resistance. But due to the
low rate of virologic failure, the low prevalence of
preexisting minority NNRTI-resistant HIV-1 variants in
ART-naive patients and a variety of other factors such as
the numerous possibilities of ART regimens, a huge
number of patients would need to be included in such
a study.
Cost effectiveness was not explicitly analysed in our study.
Our data show that applying a more sensitive drug
resistance assay in 100 patients would have prevented one
virologic failure. However, in the case of preexisting
minority NNRTI-resistant HIV-1 variants, potentially
prevented failures have to be balanced against the costs of
NNRTI-sparing regimens, which often are more costly
and less often available as single tablet regimens. As
virologic failure did not occur in most of the patients with
preexisting minority NNRTI-resistant HIV-1 variants,
this suggests that standard pretreatment screening for
minority variants will not be the most cost-effective
option.
In summary, our study shows that preexisting K103N,
Y181C or M184V variants only have a very low positive
predictive value for ART-naive patients in routine
clinical settings wherein the rate of virologic failure is
very low as it is the case for the SHCS [34]. Hence, the
number of possibly preventable virologic failures in
patients harbouring minority NNRTI-resistant HIV-1
variants was small. Noteworthy, most virologic failures
occurred without evidence for preexisting minority
NNRTI-resistant HIV-1 variants, and in contrast, most
of the patients harbouring minority NNRTI-resistant
variants did not experience virologic failure. Although
per-existing minority NNRTI-resistant HIV-1 variants
may have an impact on ART as revealed in settings of
case–control studies, the implementation of minority
NNRTI-resistant HIV-1 variant analysis in addition to
GRT cannot be recommended in routine clinical
settings. Additional associated cofactors need to be
discovered.
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